Mochida Pharmaceutical has lifted restricted shipments of G-Lasta BS, Japan's first biosimilar. Restricted shipments had continued since March 2024 in response to demand exceeding expectations, but the product will now move to regular distribution after a stable supply was secured.
Mochida Pharmaceutical has lifted restricted shipments of G-Lasta BS, Japan's first biosimilar. The article cites demand exceeding expectations as the reason restricted shipments had continued.
Restricted shipments began in March 2024, and the need to stabilize supply is said to have been behind the prolonged supply restrictions.
Nipro will also continue supplying the product, and stable supply is expected to proceed under a regular distribution system.